Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Exenatide vs Orforglipron: Exenatide has the stronger overall evidence (6 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Exenatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Exenatide and Orforglipron have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.
any
Once-weekly extended-release injection (Bydureon)
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
Weeks to months
Months
Years
Especially early / during dose escalation
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL).
N Engl J Med (2017) · Rct · n=14752
Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1): a randomised, open-label, non-inferiority study.
Lancet (2008) · Rct · n=295
30-week open-label RCT in 295 patients with type 2 diabetes comparing once-weekly extended-release exenatide 2 mg with 10 µg twice daily
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Lancet (2013) · Rct · n=911
26-week head-to-head open-label RCT in 911 patients: once-weekly exenatide 2 mg vs once-daily liraglutide 1.8 mg added to oral therapy
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Exenatide has a higher evidence score (6/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Orforglipron has a higher relevance score (70 vs 66).
No known interactions between Exenatide and Orforglipron have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.